在2期CANDELA研究中,afliberept 8 mg治疗nAMD的临床结果。

IF 5.7 Q1 OPHTHALMOLOGY
Jordana G. Fein MD , Priya S. Vakharia MD , A. Paul Chous OD , Rutvi Desai OD , Fabiana Q. Silva MD , Kimberly Reed OD , Alyson J. Berliner MD, PhD , Robert Vitti MD , Charles C. Wykoff MD, PhD
{"title":"在2期CANDELA研究中,afliberept 8 mg治疗nAMD的临床结果。","authors":"Jordana G. Fein MD , Priya S. Vakharia MD , A. Paul Chous OD , Rutvi Desai OD , Fabiana Q. Silva MD , Kimberly Reed OD , Alyson J. Berliner MD, PhD , Robert Vitti MD , Charles C. Wykoff MD, PhD","doi":"10.1016/j.oret.2025.03.023","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 9","pages":"Pages 915-918"},"PeriodicalIF":5.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical Outcomes in Neovascular Age-related Macular Degeneration with Aflibercept 8 mg in the Phase II CANDELA Study\",\"authors\":\"Jordana G. Fein MD , Priya S. Vakharia MD , A. Paul Chous OD , Rutvi Desai OD , Fabiana Q. Silva MD , Kimberly Reed OD , Alyson J. Berliner MD, PhD , Robert Vitti MD , Charles C. Wykoff MD, PhD\",\"doi\":\"10.1016/j.oret.2025.03.023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19501,\"journal\":{\"name\":\"Ophthalmology. Retina\",\"volume\":\"9 9\",\"pages\":\"Pages 915-918\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmology. Retina\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468653025001526\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Retina","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468653025001526","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

在这项对CANDELA试验进行的事后分析中,接受8毫克阿弗利百普治疗的新生血管性老年性黄斑变性患者的眼部解剖和视觉效果均有所改善,这表明与2毫克阿弗利百普相比,阿弗利百普具有治疗优势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinical Outcomes in Neovascular Age-related Macular Degeneration with Aflibercept 8 mg in the Phase II CANDELA Study
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Ophthalmology. Retina
Ophthalmology. Retina Medicine-Ophthalmology
CiteScore
7.80
自引率
6.70%
发文量
274
审稿时长
33 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信